Literature DB >> 18838963

Genetically defined EWS/FLI1 model system suggests mesenchymal origin of Ewing's family tumors.

Gary Potikyan1, Kelly A France, Marc R J Carlson, Jun Dong, Stanley F Nelson, Christopher T Denny.   

Abstract

Ewing's family tumors (EFTs) are characterized by recurrent chromosomal translocations that produce chimeric fusions between the EWS gene and one of five ETS transcription factors. The expression of EWS/FLI1, the predominant fusion product in EFTs, is believed to deregulate downstream target genes in an undefined tissue type and leads to development of EFTs. Attempts to generate model systems that represent EFTs have been hampered by an unexpected toxicity of the fusion gene. In the present study, we used gene expression analysis to identify tissue types based on the similarity of their expression profiles to those of EWS/FLI1-modulated genes. The data obtained from this screen helped to identify IMR-90 cells, a human fetal fibroblast, that upon further manipulation can maintain stable EWS/FLI1 expression without the reported toxicity. In addition, gene expression profiling of these cells revealed a significant overlap of genes that have been previously reported to be targets of EWS/FLI1. Furthermore, we show, for the first time, a partial transformation of these human primary fibroblasts with EWS/FLI1 expression. The experiments presented here provide a solid foundation for generation of a new model system for studying Ewing's sarcoma biology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18838963     DOI: 10.1038/labinvest.2008.99

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  19 in total

1.  Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro.

Authors:  Dave N T Aryee; Stephan Niedan; Maximilian Kauer; Raphaela Schwentner; Idriss M Bennani-Baiti; Jozef Ban; Karin Muehlbacher; Michael Kreppel; Robert L Walker; Paul Meltzer; Christopher Poremba; Reinhard Kofler; Heinrich Kovar
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

2.  RNA helicase A activity is inhibited by oncogenic transcription factor EWS-FLI1.

Authors:  Hayriye Verda Erkizan; Jeffrey A Schneider; Kamal Sajwan; Garrett T Graham; Brittany Griffin; Sergey Chasovskikh; Sarah E Youbi; Abraham Kallarakal; Maksymilian Chruszcz; Radhakrishnan Padmanabhan; John L Casey; Aykut Üren; Jeffrey A Toretsky
Journal:  Nucleic Acids Res       Date:  2015-01-06       Impact factor: 16.971

3.  Oncogenic fusion protein EWS/FLI1 down-regulates gene expression by both transcriptional and posttranscriptional mechanisms.

Authors:  Kelly A France; Jennifer L Anderson; Ann Park; Christopher T Denny
Journal:  J Biol Chem       Date:  2011-04-28       Impact factor: 5.157

4.  Mesenchymal Stem Cells and the Origin of Ewing's Sarcoma.

Authors:  Patrick P Lin; Yongxing Wang; Guillermina Lozano
Journal:  Sarcoma       Date:  2010-10-05

5.  Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis.

Authors:  Ashley A Kowalewski; R Lor Randall; Stephen L Lessnick
Journal:  Sarcoma       Date:  2010-11-01

6.  Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors.

Authors:  Scott A Tomlins; Nallasivam Palanisamy; J Chad Brenner; Jennifer N Stall; Javed Siddiqui; Dafydd G Thomas; David R Lucas; Arul M Chinnaiyan; Lakshmi P Kunju
Journal:  Am J Clin Pathol       Date:  2013-06       Impact factor: 2.493

Review 7.  The adolescent and young adult with cancer: state of the art -- bone tumors.

Authors:  Nino Rainusso; Lisa L Wang; Jason T Yustein
Journal:  Curr Oncol Rep       Date:  2013-08       Impact factor: 5.075

Review 8.  Ewing Sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions.

Authors:  Paul Jedlicka
Journal:  Int J Clin Exp Pathol       Date:  2010-03-19

9.  ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways.

Authors:  Alan K Ikeda; Dejah R Judelson; Noah Federman; Keith B Glaser; Elliot M Landaw; Christopher T Denny; Kathleen M Sakamoto
Journal:  Mol Cancer Ther       Date:  2010-03-02       Impact factor: 6.261

10.  A molecular function map of Ewing's sarcoma.

Authors:  Maximilian Kauer; Jozef Ban; Reinhard Kofler; Bob Walker; Sean Davis; Paul Meltzer; Heinrich Kovar
Journal:  PLoS One       Date:  2009-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.